GeoVax Labs (GOVX) Competitors $0.60 +0.02 (+2.93%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GOVX vs. ANVS, ELUT, MRSN, XFOR, PLUR, ADAP, SNTI, OKUR, MURA, and RANIShould you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Annovis Bio (ANVS), Elutia (ELUT), Mersana Therapeutics (MRSN), X4 Pharmaceuticals (XFOR), Pluri (PLUR), Adaptimmune Therapeutics (ADAP), Senti Biosciences (SNTI), OnKure Therapeutics (OKUR), Mural Oncology (MURA), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical products" industry. GeoVax Labs vs. Its Competitors Annovis Bio Elutia Mersana Therapeutics X4 Pharmaceuticals Pluri Adaptimmune Therapeutics Senti Biosciences OnKure Therapeutics Mural Oncology Rani Therapeutics Annovis Bio (NYSE:ANVS) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Is ANVS or GOVX more profitable? Annovis Bio has a net margin of 0.00% compared to GeoVax Labs' net margin of -403.88%. Annovis Bio's return on equity of -206.01% beat GeoVax Labs' return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -206.01% -158.26% GeoVax Labs -403.88%-408.80%-279.89% Do institutionals & insiders believe in ANVS or GOVX? 15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 1.2% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger earnings and valuation, ANVS or GOVX? Annovis Bio has higher earnings, but lower revenue than GeoVax Labs. Annovis Bio is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$24.59M-$2.04-1.08GeoVax Labs$3.95M2.42-$24.99M-$2.01-0.30 Which has more volatility and risk, ANVS or GOVX? Annovis Bio has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.31, meaning that its stock price is 231% more volatile than the S&P 500. Does the media prefer ANVS or GOVX? In the previous week, GeoVax Labs had 1 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for GeoVax Labs and 2 mentions for Annovis Bio. GeoVax Labs' average media sentiment score of 0.89 beat Annovis Bio's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GeoVax Labs 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ANVS or GOVX? Annovis Bio currently has a consensus target price of $17.33, suggesting a potential upside of 684.31%. GeoVax Labs has a consensus target price of $8.50, suggesting a potential upside of 1,316.67%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Annovis Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33GeoVax Labs 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryGeoVax Labs beats Annovis Bio on 8 of the 14 factors compared between the two stocks. Get GeoVax Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOVX vs. The Competition Export to ExcelMetricGeoVax LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.56M$12.26B$9.05B$10.60BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-0.3021.4785.8427.34Price / Sales2.42275.54535.76202.47Price / CashN/A47.1237.9261.55Price / Book1.2510.4313.056.78Net Income-$24.99M-$52.40M$3.30B$275.79M7 Day Performance8.11%6.37%4.81%2.64%1 Month Performance-12.92%16.15%9.99%9.14%1 Year Performance-73.09%33.90%85.26%35.89% GeoVax Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOVXGeoVax Labs2.5559 of 5 stars$0.60+2.9%$8.50+1,316.7%-70.6%$9.56M$3.95M-0.3010Analyst ForecastGap DownANVSAnnovis Bio2.4179 of 5 stars$2.03+3.2%$17.33+752.6%-72.7%$39.62MN/A-1.003News CoverageAnalyst ForecastGap UpELUTElutia3.0724 of 5 stars$0.93-6.3%$7.00+652.7%-76.7%$39.43M$24.38M-0.88180Analyst ForecastMRSNMersana Therapeutics3.9807 of 5 stars$7.79+2.9%$56.60+626.6%-81.0%$38.87M$40.50M-0.53150Analyst ForecastXFORX4 Pharmaceuticals3.9533 of 5 stars$3.35-3.2%$34.17+919.9%-79.5%$38.22M$2.56M-0.2380Analyst ForecastPLURPluri1.713 of 5 stars$4.61-0.9%$12.00+160.3%-13.0%$37.62M$1.34M-0.89150News CoverageAnalyst ForecastGap UpADAPAdaptimmune Therapeutics2.9047 of 5 stars$0.14-4.8%$1.35+865.5%-76.8%$37.11M$178.03M-0.22490News CoverageAnalyst ForecastOptions VolumeGap UpSNTISenti Biosciences1.9627 of 5 stars$1.40+0.7%$8.50+507.1%-25.2%$36.62M$2.56M-0.164Analyst ForecastOKUROnKure Therapeutics3.2907 of 5 stars$2.67+6.4%$32.33+1,111.0%N/A$36.13MN/A-0.56N/AAnalyst ForecastMURAMural Oncology2.841 of 5 stars$2.08-0.5%$12.00+476.9%-40.1%$36.05MN/A-0.24119Analyst ForecastRANIRani Therapeutics2.6853 of 5 stars$0.49+2.1%$7.33+1,396.6%-77.6%$35.22M$1.03M-0.54110Analyst ForecastGap Up Related Companies and Tools Related Companies ANVS Competitors ELUT Competitors MRSN Competitors XFOR Competitors PLUR Competitors ADAP Competitors SNTI Competitors OKUR Competitors MURA Competitors RANI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GOVX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
